TOP2A and ovarian serous cystadenocarcinoma: The ovarian serous cystadenocarcinoma patients with TOP2A genetic alteration showed worse prognoses in overall survival (p = 2.632e-03), disease-specific survival (p = 8.530e-03), and progression-free survival (p = 2.237e-03), but not disease-free survival (p = 0.222), versus those cases without TOP2A genetic alteration (Figure 2D).